{"id":"durvalumab-olaparib-phase","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Immune-mediated pneumonitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Durvalumab is a PD-L1 inhibitor that restores T-cell-mediated anti-tumor immunity by blocking the PD-L1/PD-1 checkpoint. Olaparib is a PARP inhibitor that causes synthetic lethality in BRCA-mutant or homologous recombination-deficient cancers by preventing DNA repair. The combination aims to enhance immunogenicity while exploiting DNA repair defects.","oneSentence":"Durvalumab blocks PD-L1 to enhance immune activation while olaparib inhibits PARP to impair DNA repair, together leveraging immunotherapy and synthetic lethality in homologous recombination-deficient tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:19.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic or locally advanced ovarian cancer (BRCA-mutant or HRD-positive)"},{"name":"Metastatic non-small cell lung cancer with BRCA mutations or HRD"}]},"trialDetails":[{"nctId":"NCT05411094","phase":"PHASE1","title":"Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-22","conditions":"Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":18},{"nctId":"NCT02484404","phase":"PHASE1, PHASE2","title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-29","conditions":"Colorectal Neoplasms, Breast Neoplasms","enrollment":268},{"nctId":"NCT03660826","phase":"PHASE2","title":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-27","conditions":"Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma","enrollment":288},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT03801369","phase":"PHASE2","title":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","status":"TERMINATED","sponsor":"Gordon Mills, MD, PhD","startDate":"2018-12-12","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT04065269","phase":"PHASE2","title":"ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-11-27","conditions":"Gynaecological Cancers","enrollment":174},{"nctId":"NCT06890273","phase":"","title":"NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-20","conditions":"Endometrial Cancer","enrollment":150},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT03459846","phase":"PHASE2","title":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-16","conditions":"Urinary Bladder Neoplasms","enrollment":154},{"nctId":"NCT02734004","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-03-17","conditions":"Ovarian, Breast, SCLC","enrollment":264},{"nctId":"NCT06746116","phase":"PHASE3","title":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-30","conditions":"Advanced or Recurrent Endometrial Cancer","enrollment":45},{"nctId":"NCT03923270","phase":"PHASE1","title":"Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-06","conditions":"Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer","enrollment":25},{"nctId":"NCT02546661","phase":"PHASE1","title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-12-28","conditions":"Muscle Invasive Bladder Cancer","enrollment":117},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT04269200","phase":"PHASE3","title":"Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-05-05","conditions":"Endometrial Neoplasms","enrollment":805},{"nctId":"NCT04728230","phase":"PHASE1, PHASE2","title":"Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-05","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":63},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT03784014","phase":"PHASE3","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-19","conditions":"Soft Tissue Sarcoma","enrollment":603},{"nctId":"NCT05568212","phase":"PHASE2","title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2022-05-02","conditions":"Non-small-cell Lung Cancer Patients","enrollment":176},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT03842228","phase":"PHASE1","title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-21","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":39},{"nctId":"NCT04644289","phase":"PHASE2","title":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","status":"RECRUITING","sponsor":"AGO Research GmbH","startDate":"2022-05-05","conditions":"Epithelial Ovarian Cancer","enrollment":60},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT06441747","phase":"PHASE2","title":"Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2024-09-23","conditions":"Cholangiocarcinoma","enrollment":40},{"nctId":"NCT04348045","phase":"PHASE2","title":"Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2020-12-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":307},{"nctId":"NCT03772561","phase":"PHASE1","title":"Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2018-12-03","conditions":"Solid Tumor, Adult","enrollment":40},{"nctId":"NCT05498155","phase":"PHASE2","title":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-11-07","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT03682289","phase":"PHASE2","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2019-01-17","conditions":"Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm","enrollment":89},{"nctId":"NCT06419179","phase":"PHASE2","title":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)","status":"ENROLLING_BY_INVITATION","sponsor":"University of Cologne","startDate":"2024-10-09","conditions":"Small Cell Lung Carcinoma","enrollment":29},{"nctId":"NCT03594396","phase":"PHASE1, PHASE2","title":"Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2018-06-29","conditions":"Breast Neoplasms","enrollment":54},{"nctId":"NCT04053322","phase":"PHASE2","title":"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2019-08-26","conditions":"ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status","enrollment":172},{"nctId":"NCT03737643","phase":"PHASE3","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-04","conditions":"Advanced Ovarian Cancer","enrollment":1407},{"nctId":"NCT05222971","phase":"PHASE2","title":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-04-01","conditions":"Biliary Tract Cancer, DNA Damage Repair Deficiency","enrollment":62},{"nctId":"NCT04538378","phase":"PHASE2","title":"Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-07","conditions":"EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine","enrollment":4},{"nctId":"NCT05255653","phase":"PHASE2, PHASE3","title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2021-11-11","conditions":"Endometrial Cancer","enrollment":1615},{"nctId":"NCT02953457","phase":"PHASE2","title":"Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-06-29","conditions":"BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma","enrollment":40},{"nctId":"NCT06650709","phase":"PHASE2","title":"NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study","status":"NOT_YET_RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2024-11-01","conditions":"Ovarian Cancer Stage IV","enrollment":40},{"nctId":"NCT03991832","phase":"PHASE2","title":"Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-12-31","conditions":"Glioma, Cholangiocarcinoma, Solid Tumor","enrollment":58},{"nctId":"NCT02937818","phase":"PHASE2","title":"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-28","conditions":"Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma","enrollment":72},{"nctId":"NCT03810105","phase":"PHASE2","title":"A Study of Olaparib and Durvalumab in Prostate Cancer","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-03-07","conditions":"Prostate Cancer","enrollment":5},{"nctId":"NCT04169841","phase":"PHASE2","title":"Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2020-02-10","conditions":"Immunotherapy","enrollment":270},{"nctId":"NCT03167619","phase":"PHASE2","title":"Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Triple Negative Breast Cancer","enrollment":45},{"nctId":"NCT04015739","phase":"PHASE2","title":"Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse","status":"UNKNOWN","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2019-03-01","conditions":"Epithelial Ovarian Cancer, Relapse","enrollment":74},{"nctId":"NCT05245994","phase":"PHASE2","title":"An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese","status":"UNKNOWN","sponsor":"Li Zhang, MD","startDate":"2021-08-21","conditions":"Lung Cancer, Small Cell Lung Cancer, Durvalumab","enrollment":60},{"nctId":"NCT04579133","phase":"PHASE2","title":"Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy","status":"TERMINATED","sponsor":"Latin American Cooperative Oncology Group","startDate":"2021-03-01","conditions":"Bladder Cancer, Urothelial Carcinoma","enrollment":140},{"nctId":"NCT02882308","phase":"PHASE2","title":"Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2016-10-20","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Maintenance phase"],"phase":"phase_3","status":"active","brandName":"Durvalumab + Olaparib phase","genericName":"Durvalumab + Olaparib phase","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Durvalumab blocks PD-L1 to enhance immune activation while olaparib inhibits PARP to impair DNA repair, together leveraging immunotherapy and synthetic lethality in homologous recombination-deficient tumors. Used for Metastatic or locally advanced ovarian cancer (BRCA-mutant or HRD-positive), Metastatic non-small cell lung cancer with BRCA mutations or HRD.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}